Table 4: Reasons why clinicians did not order or recommend various cancer genomic tests among clinicians who do not order that specific test.

Not familiar with test 
(%)a  
(95%  CI)b
Clinical outcomes would not change  
(%)a  
(95%  CI)b
Costs too much/insurance will not cover it  
(%)a  
(95%  CI)b
Test not valid  
(%)a  
(95%  CI)b
Practice guidelines do not include this test  
(%)a  
(95%  CI)b
Test not relevant
to patients  
(%)a  
(95%  CI)b

OncoVuec,d787 (79.0%)24 (2.4%)106 (10.6%)11 (1.1%)173 (17.4%)75 (7.5%)
(76.45%–81.4%)(1.6%–3.6%)(8.9%–12.7%)(0.6%–2.0%)(15.1%–19.9%)(6.1%–9.3%)

Fecal DNAe783 (71.8%)37 (3.4%)119 (10.9%)47 (4.3%)216 (19.8%)57 (5.3%)
(69.1%–74.4%)(2.5%–4.7%)(9.2%–12.9%)(3.3%– 5.7%)(17.6%–22.3%)(4.1%–6.7%)

Tumor gene
expression
profilesf,g
126 (50.6%)14 (5.6%)21 (8.4%) 6 (2.4%)17 (6.8%)21 (8.4%)
(44.4%–56.8%)(3.3%–9.3%)(5.6%–12.6%)(1.1%–5.3%)(4.3%–10.7%)(5.5%–12.6%)

CYP2D6 131 (42.1%)10 (3.2%)10 (3.2%)4 (1.3%)19 (6.1%)96 (30.9%)
(36.7%–47.7%)(1.7%–5.9%)(1.7%–5.9%)(0.5%–3.4%)(3.9%–9.4%)(26.0%–36.3)h

UGT1A1 187 (58.4%) NAj7 (2.2%) NAj16 (5.0%)126 (39.4%)
(52.9%–63.7%)(1.0%–4.5%)(3.1%–8.0%)(34.1%–44.9%)k

KRAS 108 (40.3%) NAj4 (1.5%) NAj9 (3.4%)127 (47.4%)
(34.6%–46.3%)(0.6%–3.9%)(1.7%–6.4%)(41.4%–53.4%)l

aThe column % reflects the percent responding within each practice category.
bCI: confidence interval.
cOncoVue is a multigene screening panel for patients without breast cancer.
dAmong clinicians who recommend breast and ovarian screening to patients without breast cancer.
eAmong clinicians who recommend colorectal cancer screening to patients without colorectal cancer.
fBreast cancer tumor gene expression profiles include Oncotype DX, MammaPrint, and H/I ratio.
gAmong clinicians who treat patients for breast cancer.
hTest not relevant to patients because clinician does not prescribe tamoxifen to patients.
iAmong clinicians who treat patients for colorectal cancer.
jUnable to report estimates due to small cell size.
kTest not relevant to patients because clinician does not prescribe irinotecan to patients.
lTest not relevant to patients because clinician does not prescribe anti-EGFR therapy to patients.